[3-(2-Bromoethoxy)phenyl] acetate | 1428333-04-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: [3-(2-Bromoethoxy)phenyl] acetate
• CAS: 1428333-04-3
• 化学式: C₁₀H₁₁BrO₃
• 分子量: 259.1
• InChiKey: XRAQSZYWYXEHDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [3-(2-Bromoethoxy)phenyl] acetate 在 盐酸 、 palladium on activated charcoal 、 氢气 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 12.0h， 生成 N-[2-[2-(3-hydroxyphenoxy)ethyl]-1,3-dioxoisoindol-5-yl]-4-methylbenzenesulfonamide
  参考文献：
  名称：

  A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as α-glucosidase inhibitors

  摘要：

  Several members of a new family of non-sugar-type alpha-glycosidase inhibitors, bearing a 5-(p-toluenesulfonylamino)phthalimide moiety and various substituent at the N2 position, were synthesized and their activities were investigated. The newly synthesized compounds displayed different inhibition profile towards yeast alpha-glycosidase and rat intestinal alpha-glycosidase. Almost all the compounds had strong inhibitory activities against yeast alpha-glycosidase. Regarding rat intestinal alpha-glycosidase, only analogs with N2-aromatic substituents displayed varying degrees of inhibitory activities on rat intestinal maltase and lactase and nearly all compounds showed no inhibition against rat intestinal alpha-amylase. Structure-activity relationship studies indicated that 5-(p-toluenesulfonylamino)phthalimide moiety is a favorable scaffold to exert the alpha-glucosidase inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.011

文献信息

• NOVEL ADENINE COMPOUND
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1939199A1

  公开（公告）日：2008-07-02

  An adenine compound useful as a medicine represented by the following formula (1): [wherein R1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.; X is oxygen atom, sulfur atom, a single bond, etc.; A1 is optionally substituted and optionally saturated 4 to 8 membered heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom; A2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group; L1 and L2 are independently, substituted straight or branched alkylene or a single bond, etc.; L3 is optionally substituted straight or branched alkylene, etc.; R2 is hydrogen atom, optionally substituted alkyl group.] or its pharmaceutically acceptable salt.

  由下式(1)表示的一种可用作药物的腺嘌呤化合物： [其中 R1 是卤素原子、任选取代的烷基、任选取代的芳基等； X 是氧原子、硫原子、单键等； A1 是任选取代的和任选饱和的 4 至 8 个成员的 A1 是任选取代且任选饱和的 4 至 8 个成员的杂环基团，含有 1 至 2 个选自 1 至 3 个氮原子、0 至 1 个氧原子和 0 至 1 个硫原子的杂原子； A2 是任选取代的 6 至 10 个环芳烃基团或任选取代的 5 至 10 个杂环芳烃基团； L1 和 L2 独立地是取代的直链或支链亚烷基或单键等； L3 是任选取代的直链或支链亚烷基等； R2 是氢原子、任选取代的烷基]。 或其药学上可接受的盐。